Comparing hypnosis and supportive counselling as psychological treatments for Amyotrophic Lateral Sclerosis (ALS)

Psychological Intervention in Amyotrophic Lateral Sclerosis: Comparing Hypnosis and Supportive Counselling

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11845385

Enrollment

Registered

2019-05-09

Start date

2012-06-11

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis Nervous System Diseases Motor neuron disease

Interventions

Treatment 1: Hypnosis-based intervention Treatment 2: Supportive Counselling Treatment Both treatments consisted of 4 weekly domiciliary sessions lasting 60 minutes eac

and to help them accept their feelings, and share them with family and friends, counting on their empathic reactions and support. Psychoeducational aspects were included in the intervention sessions a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Probable or confirmed sporadic ALS according to the revised El Escorial criteria

Exclusion criteria

Exclusion criteria: 1. Significant neuropsychological impairments 2. Concomitant psychiatric disorders 3. Concomitant neurological disorders 4. Using high-dose psychoactive drugs

Design outcomes

Primary

Measure	Time frame
1. Anxiety and depression are measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, at the end of treatment (only for the treated groups), and 3 and 6 months after the treatment. 2. Global quality of life is measured using the Amyotrophic Lateral Sclerosis Specific Quality of Life – Revised (ALSSQOL-R) at baseline, at the end of treatment (only for the treated groups), and 3 and 6 months after the treatment.	—

Measure

Time frame

1. Anxiety and depression are measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, at the end of treatment (only for the treated groups), and 3 and 6 months after the treatment. 2. Global quality of life is measured using the Amyotrophic Lateral Sclerosis Specific Quality of Life – Revised (ALSSQOL-R) at baseline, at the end of treatment (only for the treated groups), and 3 and 6 months after the treatment.

—

Countries

Italy

Contacts

Public ContactArianna Palmieri

arianna.palmieri@unipd.it+39 049 8276672

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026